END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin

Inclusion Criteria: * Cytologic / histologic diagnosis of endometrial carcinoma * Indication for chemotherapy * Age 75 years or less * Life expectancy of at least 3 months * Measurable disease \> 1 cm Exclusion Criteria: * Previous or concomitant malignant neoplasia (not including basocellular or spinocellular skin carcinoma or in-situ carcinoma of the uterine cervix, provided they are being adequately treated) * Performance status (ECOG) \> 2 * Previous chemotherapy treatment * Heart disease (heart failure, myocardial heart attack within 6 months prior to randomization, atrioventricular block of any degree, serious arrhythmia) * Leukocytes \< 4000/mm3, platelets \< 100000/mm3 * Impaired renal function (creatinine \> o = 1.25 times the upper normal limit) or liver function (SGOT or SGPT \> o = 1.25 times the upper normal limit) * Present or suspected hemorrhagic syndromes * Uncooperative and/or unreliable patients * Patient's inability to access the center * Refusal of informed consent